comparemela.com
  1. Home
  2. Live Updates
  3. Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023 : comparemela.com

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Tokyo ,Japan ,Meiji ,Hokkaido ,Canada ,United States ,Berlin ,Germany ,Yasushi Miyazawa ,Daikichiro Kobayashi ,Seika Pharma ,European Association Of Dermatology ,Meiji Seika Pharma Co Ltd ,Meiji Pharma United States Inc ,Representative Director ,European Association ,Mean Psoriasis Area ,Severity Index ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.